Research Library › Bioregulators & Thymic
Cartagen is a product name associated with the cartilage peptide bioregulators developed at Vladimir Khavinson’s St. Petersburg Institute of Bioregulation and Gerontology. The program’s 2006 patents describe a synthetic tripeptide, AED (alanine-glutamic acid-aspartic acid), and a peptide complex extracted from young calf rib-joint cartilage. As of 22 Oct 2026 no peptide from this program is FDA-approved, and none was among the peptides the FDA reviewed in 2026.
Key facts
| Type | Short peptide bioregulator (cartilage series) |
|---|---|
| Related compounds in the literature | Synthetic tripeptide AED (Ala-Glu-Asp); calf-cartilage peptide complex; Cartalax |
| First described | Patent priority dates 30 May 2006 (AED) and 22 Jun 2006 (cartilage extract) |
| Developed by | Vladimir Khavinson, V.V. Malinin, G.A. Ryzhak and colleagues; applicant Sia Peptides LLC |
| Institution | St. Petersburg Institute of Bioregulation and Gerontology, founded 1992 |
| Proposed target | Cartilage and bone tissue (proposed in the developers' patents) |
| Regulatory status (Oct 2026) | Not FDA-approved; not under FDA compounding review; Cartalax listed as a dietary supplement in Russia |
Who developed it
The cartilage bioregulators come from the St. Petersburg Institute of Bioregulation and Gerontology, founded in 1992 by the Russian gerontologist Vladimir Khavinson [1, 2]. Two Eurasian patents with 2006 priority dates name Khavinson together with V.V. Malinin and G.A. Ryzhak (one also lists E.I. Grigoriev) as inventors, and were filed by the company Sia Peptides LLC [3, 4]. Khavinson died in 2024 [2].
The institute developed many short peptides that it called bioregulators, each proposed to correspond to a particular organ or tissue. The cartilage peptides form one branch of that larger series, alongside thymic and other tissue-specific peptides [1, 5].
The developers’ own publications do not use the name Cartagen; it appears as a product name in the research-peptide market for a member of this cartilage peptide family.
What it was designed to target
The program produced two related materials. One is a peptide complex extracted from the rib-joint cartilage of calves or pigs. The patent describes freezing, grinding and acid extraction of cartilage from calves under a year old [4]. The other is a synthetic tripeptide, AED, made of alanine, glutamic acid and aspartic acid, which the institute describes as a component of its cartilage complex [3, 5].
In the developers’ framework, such short peptides are proposed to act as tissue-specific regulators. The patents propose a role in cartilage and bone metabolism, and the AED patent also proposes interaction with calcitonin-producing thyroid cells [3, 5]. These proposals have not been confirmed outside the institute’s own research.
Why it was created
The patents were framed around degenerative conditions of the joints and spine, and named glucosamine and chondroitin as the existing options at the time [3]. The patents report experiments on rat cartilage fragments in culture, animal safety testing and small patient groups, without described randomization or blinding [3, 4].
A 2023 review from the institute cites cell studies for AED and states that the cartilage complex was in phase 2 trials in Russia, without reporting results [5]. No published randomized trial was found.
Research timeline
- 1992: St. Petersburg Institute of Bioregulation and Gerontology founded [1]
- 2006: Priority dates for the AED and cartilage-extract patents [3, 4]
- 2008: Both Eurasian patents published [3, 4]
- 2023: Institute publishes review on peptide regulation of cartilage stem cells [5]
- 2024: Vladimir Khavinson dies [2]
Regulatory status as of October 2026
No peptide from the cartilage bioregulator program is approved as a drug by the FDA. A related product, Cartalax, is listed as a dietary supplement in Russia’s main drug reference [6]. The cartilage peptides were not among the substances the FDA reviewed for compounding in 2026 [7].
No cartilage bioregulator is named on the 2026 WADA Prohibited List; its section S0 covers substances with no approval for human therapeutic use [8].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who developed the cartilage peptide bioregulators?
They were developed by Vladimir Khavinson’s St. Petersburg Institute of Bioregulation and Gerontology, with 2006 patents naming Khavinson, V.V. Malinin and G.A. Ryzhak [1, 3, 4].
What is AED?
AED is a synthetic tripeptide of alanine, glutamic acid and aspartic acid, patented in 2006 and described by the institute as a component of its cartilage peptide complex [3, 5].
Is Cartagen FDA approved?
No. As of 22 Oct 2026 no cartilage bioregulator peptide is FDA-approved, and none was among the peptides the FDA reviewed for compounding in 2026 [7].
How is Cartagen related to Cartalax?
Both names belong to the cartilage series of Khavinson-style peptide bioregulators. Cartalax is the name listed in Russia’s drug reference as a dietary supplement [6].
Sources
- Khavinson VKh. Curriculum vitae and patent list. Link
- Bumaga. Who is “Putin’s gerontologist” Vladimir Khavinson? 24 Jan 2024. Link
- Khavinson VKh, Grigoriev EI, Malinin VV, Ryzhak GA (applicant: Sia Peptides LLC). Peptide normalizing metabolism in bone and cartilaginous tissues. Eurasian patent EA010574B1 (priority 30 May 2006; published 30 Oct 2008). Link
- Khavinson VKh, Malinin VV, Ryzhak GA (applicant: Sia Peptides LLC). Preparation normalizing cartilaginous tissue, and a method for manufacturing thereof. Eurasian patent EA010724B1 (priority 22 Jun 2006; published 30 Oct 2008). Link
- Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide regulation of chondrogenic stem cell differentiation. Int J Mol Sci. 2023;24(9):8415. doi:10.3390/ijms24098415. Link
- RLS Encyclopedia (Russia). Dietary supplements index, letter К (lists Карталакс / Cartalax and Карталакс лингвал). Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
